Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Olomorasib, a highly selective and potent oral inhibitor of KRASG12C, demonstrates robust single agent and combination activity in KRASG12C-mutant models

ABSTRACT: Raw MS data for pre-published paper: Olomorasib, a highly selective and potent oral inhibitor of KRASG12C, demonstrates robust single agent and combination activity in KRASG12C-mutant models

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Junpeng Xiao

PROVIDER: PXD070323 | JPOST Repository | Wed Nov 05 00:00:00 GMT 2025

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	BAQ-E16480-031_00010_nM_A1_MS1.raw	Raw
	BAQ-E16480-031_00010_nM_A1_MS1b.raw	Raw
	BAQ-E16480-031_00010_nM_A1_MS2.raw	Raw
	BAQ-E16480-031_00010_nM_A2_MS1.raw	Raw
	BAQ-E16480-031_00010_nM_A2_MS_2.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Re-sequenced genomes of the Oriolus mellianus/traillii complex

Project description:Data for published paper

| PRJEB88494 | ENA

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

Project description: Not available

| S-EPMC11905721 | biostudies-literature

Identification of Nuclear Export Inhibitor-Based Combination Therapies in Preclinical Models of Triple-Negative Breast Cancer

Project description:An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15-20% will be diagnosed with basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but acquired chemoresistance is a common clinical problem. There is currently a lack of alternative, targeted treatment strategies for TNBC; this study sought to identify novel therapeutic combinations to treat basal-like TNBCs. For these studies, a set of four human basal-like TNBC cell lines was utilized to determine the cytotoxicity profile of 1,363 unique clinically-used drugs. Ten promising therapeutic candidates were identified, and synergism studies were performed in vitro. Two drug combinations that included KPT-330, an XPO1 inhibitor, were synergistic in all four cell lines. In vivo testing of four basal-like patient-derived xenografts identified a combination, KPT-330 and GSK2126458 (a PI3K/mTOR inhibitor), that decreased tumor burden in mice significantly more than monotherapy with either single agent. Bulk and single-cell RNA-sequencing, immunohistochemical studies, and analysis of published genomic datasets found that XPO1 was abundantly expressed in human basal-like TNBC cell lines, patient-derived xenografts, and patient tumor samples; within basal-like patients, XPO1 overexpression was associated with greater rates of metastases. These studies identify a promising new combination therapy for patients with basal-like TNBC.

2021-10-20 | GSE174391 | GEO

Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.

Project description: Not available

| S-EPMC4948304 | biostudies-literature

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma

Project description:ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma

| PRJNA1451524 | ENA

Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (OATL4).

Project description:Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (OATL4).

| PRJNA708286 | ENA

Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (Su9T01).

Project description:Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (Su9T01).

| PRJNA708289 | ENA

Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (ED).

Project description:Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (ED).

| PRJNA708285 | ENA

Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (HuT102).

Project description:Highly selective HSP90 inhibitor, pimitespib, demonstrates its potent growth suppressive activity to adult T-cell leukemia in preclinical models (HuT102).

| PRJNA708284 | ENA

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.

Project description: Not available

| S-EPMC4599239 | biostudies-literature